*
*Hemangioendothelioma|403980002
*
*
is
used to|394850002
describe
a group|261586004|160481000|389109008
of vascular neoplasms|126736007
that
may
be
considered
benign|30807003
or
malignant|21594007
in their activity.|48761009|55561003|258745004|257733005

They
have
been
described
as masses|300848003|118538004
that
fall|1912002
between a hemangioma|400210000
and
angiosarcoma.|403977003

They
are
vascular tumors|126736007
that commonly
present|52101004|246105001
with an enlarging mass|260376009|300848003|260376009|118538004
and
most commonly|4757001
involve|248448006
the lungs,|39607008
liver,|10200004|181268008
and
musculoskeletal system,|26107004|278858007
although
many other body sites|74964007|116677004
have
been
reported|229059009|223458004
,
including|55919000
the head|69536005|302548004
and
neck,|45048000|302550007
intestines,|261093006
lymph nodes,|59441001
pleura,|3120008|181609007
retroperitoneum,|260642009
stomach.|69695003|181246003

Treatment|276239002|416118004
is
varied
and
depends
on the site|10546003
and
extent|255590007
of tumor involvement,|108369006|248448006
site|10546003
(s)
of metastasis,|128462008
and
specific individual factors.|69658003|125676002|69658003|385435006

Surgical resection,|118292001|128303001
radiotherapy,|419815003|108290001
and
chemotherapy|416608005|367336001
have
all
been
used|394850002
to
treat|395077000
these masses,|300848003|118538004
although
studies|110465008|224699009
on survival
have
yet to
be
conducted|844005
to
delineate
various treatment regimens.|256220008|276239002|256220008|416118004

M
:
VAS|273903006

anat(
a
:
h/u/t/a/l,v:h/u/t/a/l/phys/devp/cell/prot|4421005|304383000|362837007|304383000

noco/syva/cong/lyvd/tumr,
sysi/epon,
injr

proc,
drug|410942007
(C2s+n/3/4/5/7/8/9

